Covid-19: WHO sounds warning over fast-spreading Omicron variant

Says Omicron is evading some immune responses; China must share more data on virus origins

Omicron, Covid,
Stephanie Nebehay and Emma Farge | Reuters Geneva
3 min read Last Updated : Dec 21 2021 | 1:23 AM IST
The Omicron variant of the coronavirus is spreading faster than the Delta variant and is causing infections in people already vaccinated or who have recovered from the COVID-19 disease, the head of the World Health Organization (WHO) said on Monday.

WHO chief scientist Soumya Swaminathan added it would be "unwise" to conclude from early evidence that Omicron was a milder variant that previous ones.

"... with the numbers going up, all health systems are going to be under strain," Soumya Swaminathan told Geneva-based journalists.

The variant is successfully evading some immune responses, she said, meaning that the booster programmes being rolled out in many countries ought to be targeted towards people with weaker immune systems.

"There is now consistent evidence that Omicron is spreading significantly faster than the Delta variant," WHO director-general Tedros Adhanom Ghebreyesus told the briefing.

"And it is more likely people vaccinated or recovered from COVID-19 could be infected or re-infected," Tedros said.

Their comments echoed the finding of study by Imperial College London, which said last week the risk of reinfection was more than five times higher and it has shown no sign of being milder than Delta.

WHO officials said however that other forms of immunity vaccinations may prevent infection and disease.

While the antibody defences from some actions have been undermined, there has been hope that T-cells, the second pillar of an immune response, can prevent severe disease by attacking infected human cells.

WHO expert Abdi Mahamud added: "Although we are seeing a reduction in the neutralisation antibodies, almost all preliminary analysis shows T-cell mediated immunity remains intact, that is what we really require." However, highlighting how little is known about how to handle the new variant that was only detected last month, Swaminathan also said: "Of course there is a challenge, many of the monoclonals will not work with Omicron." She gave no details as she referred to the treatments that mimic natural antibodies in fighting off infections. Some drug makers have suggested the same.

Ending The Pandemic

In the short term, Tedros said that holiday festivities would in many places lead to "increased cases, overwhelmed health systems and more deaths" and urged people to postpone gatherings.

"An event cancelled is better than a life cancelled," he said.

But the WHO team also offered some hope to a weary world facing the new wave that 2022 would be the year that the pandemic, which already killed more than 5.6 million people worldwide, would end.

It pointed towards the development of second and third generation vaccines, and the further development of antimicrobial treatments and other innovations.

"(We) hope to consign this disease to a relatively mild disease that is easily prevented, that is easily treated," Mike Ryan, the WHO's top emergency expert, told the briefing.

"If we can keep virus transmission to minimum, then we can bring the pandemic to an end."

However Tedros also said China, where the SARS-CoV-2 coronavirus was first detected at the end of 2019, must be forthcoming with data and information related to its origin to help the response going forward.

"We need to continue until we know the origins, we need to push harder because we should learn from what happened this time in order to (do) better in the future," Tedros said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineCoronavirus TestsWHO

Next Story